Eric Venker Sells 75,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 75,000 shares of Roivant Sciences stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $22.53, for a total value of $1,689,750.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at $37,278,070.41. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total transaction of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.85, for a total transaction of $4,170,000.00.
• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.22, for a total transaction of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total transaction of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The stock was sold at an average price of $16.93, for a total transaction of $7,020,583.19.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The stock was sold at an average price of $17.05, for a total value of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total value of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total value of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The stock was sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The shares were sold at an average price of $16.34, for a total value of $2,800,610.64.

Roivant Sciences Stock Down 0.3%

Roivant Sciences stock opened at $21.63 on Wednesday. The business’s 50-day simple moving average is $20.73 and its 200 day simple moving average is $15.67. The stock has a market cap of $15.04 billion, a price-to-earnings ratio of -38.63 and a beta of 1.22. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $23.47.

Analyst Ratings Changes

Several equities research analysts have recently commented on ROIV shares. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a research report on Thursday, December 18th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. JPMorgan Chase & Co. upped their target price on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Bank of America increased their price target on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, September 18th. Finally, Jefferies Financial Group lifted their price objective on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.19.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently bought and sold shares of ROIV. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares in the last quarter. Swiss Life Asset Management Ltd bought a new position in Roivant Sciences during the third quarter worth about $217,000. Danske Bank A S bought a new position in Roivant Sciences during the third quarter worth about $138,000. XTX Topco Ltd acquired a new position in Roivant Sciences in the third quarter valued at about $1,067,000. Finally, Alyeska Investment Group L.P. increased its holdings in shares of Roivant Sciences by 326.7% in the third quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock worth $7,481,000 after acquiring an additional 378,589 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.